Mallory Chavannes
Contact
SC-CTSI: Mentored Career Development in Clinical and Translational Research, 2020-2023
American Gastroenterology Association: Pfizer Pilot Research Award, 2020-2021
J Can Assoc Gastroenterol. 2020 Oct; 3(5):216-221. . View in PubMed
Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis J Crohns Colitis. 2020 Jan 01; 14(1):46-52. . View in PubMed
Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study J Crohns Colitis. 2019 Apr 26; 13(5):578-584. . View in PubMed
Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease BMJ Open. 2019 04 14; 9(4):e027043. . View in PubMed
Diagnosis by peritoneal scintigraphy of peritoneal dialysis-associated hydrothorax in an infant Perit Dial Int. 2014 Jan-Feb; 34(1):140-3. . View in PubMed
The need for ongoing monitoring of adherence to access targets Pediatr Nephrol. 2013 May; 28(5):831-2. . View in PubMed
Location of parathyroid adenomas: 7-year experience J Otolaryngol Head Neck Surg. 2010 Oct; 39(5):551-4. . View in PubMed
Dr. Chavannes, research focus has been on the evaluation of therapies in inflammatory bowel diseases. Her paper on “The Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with Inflammatory Bowel Disease” was presented both at ECCO (European Crohn’s & Colitis Organization) meeting in Barcelona in 2017 and at DDW in Chicago in May 2017. Her research interest is in finding non-invasive ways of monitoring disease activity in children with inflammatory bowel disease.
